Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for AZD4547

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for AZD4547?

AZD4547 is an investigational drug.

There have been 15 clinical trials for AZD4547. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2014.

The most common disease conditions in clinical trials are Lung Neoplasms, Breast Neoplasms, and Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Southwest Oncology Group.

There are seventeen US patents protecting this investigational drug and one hundred and twenty-nine international patents.

Recent Clinical Trials for AZD4547
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerAstraZenecaPhase 1
Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"Assistance Publique - Hôpitaux de ParisPhase 1/Phase 2
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or LymphomasNational Cancer Institute (NCI)Phase 2

See all AZD4547 clinical trials

Clinical Trial Summary for AZD4547

Top disease conditions for AZD4547
Top clinical trial sponsors for AZD4547

See all AZD4547 clinical trials

US Patents for AZD4547

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD4547   Start Trial Methods for treating cancer by inhibiting FGFR3/TACC3 fusion protein Astellas Pharma Inc. (Tokyo, JP)   Start Trial
AZD4547   Start Trial Deuterated triazolopyridazine as a kinase modulator Janssen Pharmaceutica NV (Beerse, BE)   Start Trial
AZD4547   Start Trial Fusion proteins and methods thereof The Trustees of Columbia University in the City of New York (New York, NY)   Start Trial
AZD4547   Start Trial Compounds AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD4547   Start Trial FGFR gatekeeper mutant gene and drug targeting same Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD4547

Drugname Country Document Number Estimated Expiration Related US Patent
AZD4547 Australia 2013228389 2032-03-08   Start Trial
AZD4547 Brazil 112014021897 2032-03-08   Start Trial
AZD4547 Canada 2865388 2032-03-08   Start Trial
AZD4547 China 104379740 2032-03-08   Start Trial
AZD4547 Eurasian Patent Organization 029140 2032-03-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.